

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form 8-K

RENHUANG PHARMACEUTICALS INC

Form 8-K

January 17, 2007

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 8, 2006

Renhuang Pharmaceuticals, Inc.  
(Exact name of registrant as specified in its charter)

Nevada  
(State or Other Jurisdiction of Incorporation)

0-24512 88-1273503  
(Commission File Number) (IRS Employer Identification Number)

No. 281, Taiping Road, Taiping District,  
Harbin, Heilongjiang Province, 150050  
P. R. China  
(Address of Principal Executive Offices)

+86-451-5762-0378  
(Registrant's Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

Item 7.01 Regulation FD Disclosure.  
-----

Edgar Filing: RENHUANG PHARMACEUTICALS INC - Form 8-K

On December 8, 2006, Renhuang Pharmaceuticals, Inc (the "Company") issued a press release announcing a new Ginseng product. A copy of the press release is attached as Exhibit 99 to this report and is being furnished to the SEC and shall not be deemed "filed" for any purpose.

Item 9.01 Financial Statements, Pro Form Financial Information and Exhibits.  
(c) Exhibits.

EXHIBITS

Exhibit	Description
----- 99.1	----- Press Release dated December 8, 2006.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Renhuang Pharmaceuticals, Inc.

Date: December 8, 2006

By: /s/ Shaoming Li

-----  
Shaoming Li  
Chief Executive Officer and President